Artificial intelligence (AI) vendors are partnering with health care providers to identify practical challenges and consider AI technology as a potential solution. This type of collaboration is crucial to successful AI adoption because the technology is designed to tackle real-world health care problems. A myriad of examples was displayed at the recent RSNA 2020 meeting.

Since receiving approval for the first broad-panel diagnostic test as a combination product to detect cancer, Foundation Medicine has ramped up its partnerships with pharmaceutical companies and other stakeholders. The company expects to receive a similar approval for a broad-panel liquid biopsy genomic test in the first half of 2020.

The US FDA recently published four guidance documents, two final — one concerning antimicrobial susceptibility test system devices and another related to devices with physiologic closed-loop control technology. The agency’s two draft documents pertain to electronic submissions for de novo requests and graft-versus-host diseases.